100 related articles for article (PubMed ID: 10123669)
1. Findings halt clinical trials of centoxin.
Wagner M
Mod Healthc; 1993 Jan; 23(4):16. PubMed ID: 10123669
[No Abstract] [Full Text] [Related]
2. [Immunotherapy of severe gram-negative bacterial infections. Centoxin: a new drug under monitoring. National Committee for the Evaluation of Centoxin].
Pathol Biol (Paris); 1992 Dec; 40(10):975-6. PubMed ID: 1299810
[No Abstract] [Full Text] [Related]
3. Centoxin: the full story of its withdrawal.
Andrews PA
Br J Hosp Med; 1993 Apr 7-20; 49(7):517. PubMed ID: 8490693
[No Abstract] [Full Text] [Related]
4. Centoxin: the full story of its withdrawal.
Choyce MQ
Br J Hosp Med; 1993 Apr 7-20; 49(7):517. PubMed ID: 8490694
[No Abstract] [Full Text] [Related]
5. Monoclonal antibodies for gram-negative sepsis.
Med Lett Drugs Ther; 1991 Nov; 33(856):103-4. PubMed ID: 1943976
[No Abstract] [Full Text] [Related]
6. [Septomonab (Centoxin) in the treatment of gram-negative septicemia].
Fomsgaard A
Ugeskr Laeger; 1993 Apr; 155(14):1066-71. PubMed ID: 8497944
[No Abstract] [Full Text] [Related]
7. [Monoclonal antibodies and gram-negative bacterial sepsis: is their use really justified?].
Alsar MJ; Sánchez-Palacios M
Med Clin (Barc); 1993 Sep; 101(7):278. PubMed ID: 7746010
[No Abstract] [Full Text] [Related]
8. P & T Committee response to evolving technologies: preparing for the launch of high-tech, high-cost products. Roundtable discussion.
Seltzer JL; Wordell CJ; Nash D; Johnson NE; Gottlieb JE
Hosp Formul; 1992 Apr; 27(4):379-80, 386-92. PubMed ID: 10117768
[TBL] [Abstract][Full Text] [Related]
9. Biologicals: new horizons in pharmaceutical development.
Oldham RK
J Biol Response Mod; 1983; 2(3):199-206. PubMed ID: 6358418
[No Abstract] [Full Text] [Related]
10. FDA requires further trials for antiendotoxin monoclonal antibody products.
Am J Hosp Pharm; 1992 Aug; 49(8):1848, 1850. PubMed ID: 1442827
[No Abstract] [Full Text] [Related]
11. Centoxin.
Davidson J; Tarlow M
Br J Hosp Med; 1993 Jan 20-Feb 2; 49(2):121-2. PubMed ID: 8435673
[TBL] [Abstract][Full Text] [Related]
12. Can 'double blockbuster' strengthen Amgen's backbone?
Sheridan C
Nat Biotechnol; 2008 Apr; 26(4):361-3. PubMed ID: 18391999
[No Abstract] [Full Text] [Related]
13. Monoclonal antibody successes in the clinic.
Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC
Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394
[TBL] [Abstract][Full Text] [Related]
14. New immunotherapies for sepsis.
Young LS; Wenzel RP
Proc Assoc Am Physicians; 1995 Oct; 107(3):361-4. PubMed ID: 8608423
[No Abstract] [Full Text] [Related]
15. Criteria for use of antiendotoxin monoclonal antibodies (HA-1A and E5) in adult and pediatric inpatients.
Shepherd MF
Clin Pharm; 1992 Mar; 11(3):257-60. PubMed ID: 1611816
[No Abstract] [Full Text] [Related]
16. Novel immunotherapeutic approaches to the treatment of infections caused by Gram-negative bacteria.
Palliyil S; Broadbent ID
Curr Opin Pharmacol; 2009 Oct; 9(5):566-70. PubMed ID: 19726227
[TBL] [Abstract][Full Text] [Related]
17. The economic impact of HA-1A (Centoxin) against endotoxin.
Barriere SL
Pharmacoeconomics; 1992 Nov; 2(5):408-13. PubMed ID: 10147053
[TBL] [Abstract][Full Text] [Related]
18. Single versus combined antibiotic therapy for gram-negative infections.
Klibanov OM; Raasch RH; Rublein JC
Ann Pharmacother; 2004 Feb; 38(2):332-7. PubMed ID: 14742774
[TBL] [Abstract][Full Text] [Related]
19. Sepsis management and antiendotoxin therapy after nebacumab. A reappraisal.
Hurley JC
Drugs; 1994 Jun; 47(6):855-61. PubMed ID: 7521827
[No Abstract] [Full Text] [Related]
20. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis.
Falagas ME; Kasiakou SK
Infection; 2007 Feb; 35(1):3-10. PubMed ID: 17297582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
